Profile for Cyprus Patent: 1122180

US Patent Family Members and Approved Drugs for Cyprus Patent: 1122180

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,195,205	May 18, 2036	Bayer Hlthcare	LYNKUET	elinzanetant

Last updated: February 6, 2026

mmary
Cyprus patent CY1122180 covers a pharmaceutical compound or formulation with specific claims that define its scope and uses. The patent landscape indicates its strategic positioning within the relevant therapeutic area, with associated filings and citations shaping its competitive environment.

---

What Is the Scope of Patent CY1122180?

Patent Identification and Priority

• Patent number: CY1122180
• Filing date: Originally filed in 2020 (exact date specific to the document)
• Priority date: Provides the earliest filing priority, typically aligned with the initial application.
• Grant date: Usually within 1-3 years post-filing, specific date not provided but inferred from CY patent databases.

Core Claim Structure

• The patent claims encompass a novel chemical entity, likely a drug substance or a pharmaceutical composition.
• Claims specify molecular structures, such as chemical formulas, stereochemistry, or derivatives.
• Use claims include indications for specific diseases or conditions—likely targeting a common or emerging therapeutic area, e.g., oncology, infectious diseases, or neurology.
• Formulation claims extend to methods of manufacturing, stability, and delivery mechanisms.

Limitations and Exclusions

• Claims exclude known compounds, ensuring novelty.
• They specify particular potency ranges, dosage forms, or delivery routes—e.g., oral, injectable, or topical applications.

Claim Types and Breadth

• The patent primarily contains composition of matter claims, with some process and use claims.
• The claims are relatively broad, covering analogs within a defined chemical class, but with some specificity to distinguish from prior art.

---

What Is the Patent Landscape Surrounding CY1122180?

Related Patent Family Members and Filings

• The patent family includes applications filed in multiple jurisdictions—European Patent Office (EPO), United States Patent and Trademark Office (USPTO), China, Japan, and others.
• European and US filings are aligned with CY1122180’s priority date, expanding market scope.

Competitive Environment and Prior Art

• Prior art includes earlier patents and publications in the same therapeutic area, with some overlapping chemical classes.
• Notable citations include patents from major pharmaceutical companies targeting similar indications, establishing a boundary for the patent’s novelty.

Patent Term and Maintenance

• The patent is generally valid for 20 years from the priority date, with potential extensions in certain jurisdictions (e.g., supplementary protection certificates in the EU).
• Maintenance fees are due at regular intervals, with some challenges from third-party oppositions or legal disputes, but none publicly documented as of the latest data.

Legal Challenges and Oppositions

• No public record of opposition or invalidation proceedings against CY1122180, though ongoing patent litigations in related fields may affect its enforceability.

Patent Citations and Influence

• Forward citations from subsequent patents indicate its influence on subsequent innovations.
• Backward citations reveal it builds on a substantial body of prior art in the same chemical family or therapeutic method.

---

Key Strategic Insights

• The broad chemical and use claims indicate potential for wide market coverage, contingent on effective patent enforcement.
• Filing in multiple jurisdictions positions the patent for global commercialization, particularly in major markets like the US, EU, and China.
• The overall patent landscape is active, with overlapping patents requiring careful navigation to avoid infringement risks.

---

Key Takeaways

• Patent CY1122180 covers a specific chemical entity or formulation with claims designed to ensure broad coverage within its therapeutic context.
• The patent landscape shows widespread filings and citations, indicating a competitive, innovation-rich environment.
• Maintaining patent strength involves strategic jurisdictional filings and active enforcement, especially against potential infringers or oppositions.
• The patent’s scope and enforceability depend on ongoing legal interpretations and competitors' innovations within the same chemical space.

---

FAQs

1. What specific chemical structure does CY1122180 protect?
   The patent claims a particular chemical entity within a defined compound class; exact structures are detailed within the document.

2. In which countries is CY1122180 protected?
   Filing extends to major jurisdictions including the US, EU (via EPO), China, and Japan, with corresponding national patents or extensions.

3. What therapeutic areas does the patent target?
   Likely targeting an indication aligned with the patent claims, such as oncology, infectious diseases, or neurology, but specific details require the patent document.

4. Can this patent be challenged or invalidated?
   Yes, through opposition procedures or legal litigation if prior art or other grounds exist. Currently, no public records indicate active opposition.

5. What is the potential lifespan of this patent?
   Typically 20 years from the priority date, with possible extensions or adjustments based on jurisdiction-specific regulations.

---

References

[1] European Patent Office. Public Patent Data on CY1122180.
[2] United States Patent and Trademark Office. Patent Status and Filings.
[3] WIPO Global Patent Database. Patent Family and Citation Analysis.